A detailed history of Avantax Advisory Services, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Avantax Advisory Services, Inc. holds 5,950 shares of BMRN stock, worth $406,087. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,950
Previous 4,320 37.73%
Holding current value
$406,087
Previous $303,000 29.04%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 07, 2025

BUY
$61.93 - $70.49 $100,945 - $114,898
1,630 Added 37.73%
5,950 $391,000
Q3 2024

Nov 13, 2024

SELL
$69.02 - $93.84 $6,073 - $8,257
-88 Reduced 2.0%
4,320 $303,000
Q2 2024

Aug 09, 2024

BUY
$74.43 - $92.22 $74,206 - $91,943
997 Added 29.23%
4,408 $362,000
Q1 2024

May 08, 2024

BUY
$83.81 - $99.0 $285,875 - $337,689
3,411 New
3,411 $297,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.7B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Avantax Advisory Services, Inc. Portfolio

Follow Avantax Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Advisory Services, Inc. with notifications on news.